Original articlePathologic Epithelial and Anterior Corneal Nerve Morphology in Early-Stage Congenital Aniridic Keratopathy
Section snippets
Study Criteria and Subjects
All subjects with aniridia had participated in a previous study of congenital aniridia in Sweden and Norway.4, 5 In that study, a total of 124 patients with aniridia (79 in Sweden and 45 in Norway) were traced and recorded. From the Swedish cohort, 16 subjects were recruited for the present study, based on a practical limitation of those residing in regions surrounding the 2 academic hospitals where full examinations could be conducted. Subjects were specifically selected to study early-stage
Patient Characteristics
The pedigrees of the 5 families examined are shown in Figure 2 (available at http://aaojournal.org). Results of the clinical examinations, indexed by a code indicating pedigree position, are given in Table 2 (available at http://aaojournal.org). Because of light sensitivity or ocular surface irritation in some subjects with aniridia, noncompliance during examination resulted in incomplete clinical data. The mean age was 31 years (range, 18–52 years) in subjects with aniridia and 37 years
Discussion
The goal of this study was to document clinical and morphologic corneal findings in the early stages of aniridic keratopathy. In an earlier study, slit-lamp examination showed absence of palisades of Vogt and superficial corneal vascularization in 16 of 16 aniridic eyes, 9 of which had clear central cornea.19 On the basis of this result and findings in other studies,5, 25, 26 we believe that under careful examination, most if not all cases of congenital aniridia can be found to have some degree
References (38)
- et al.
Effects of PAX6 mutations on retinal function: an electroretinographic study
Am J Ophthalmol
(1998) - et al.
Markedly increased central corneal thickness: an unrecognized finding in congenital aniridia
Am J Ophthalmol
(2004) - et al.
A progressive anterior fibrosis syndrome in patients with postsurgical congenital aniridia
Am J Ophthalmol
(2005) - et al.
Evolving concepts on the pathogenetic mechanisms of aniridia related keratopathy
Int J Biochem Cell Biol
(2005) - et al.
Developmental and cellular factors underlying corneal epithelial dysgenesis in the Pax6+/- mouse model of aniridia
Exp Eye Res
(2005) - et al.
Association of aniridia and dry eyes
Ophthalmology
(2005) - et al.
Markedly increased central corneal thickness: an undiagnosed finding in congenital aniridia
Am J Ophthalmol
(2004) - et al.
Anatomy of the human corneal innervation
Exp Eye Res
(2010) - et al.
PAX6 mutations reviewed
Hum Mutat
(1998) - et al.
Genetics of aniridia and anterior segment dysgenesis
Br J Ophthalmol
(1996)
Epidemiology of aniridia in Sweden and Norway
Acta Ophthalmol
Corneal involvement in congenital aniridia
Cornea
Aniridia among children and teenagers in Sweden and Norway
Acta Ophthalmol
Corneal abnormalities in Pax6+/- small eye mice mimic human aniridia-related keratopathy
Invest Ophthalmol Vis Sci
Cytoskeletal and cell adhesion defects in wounded and Pax6+/- corneal epithelia
Invest Ophthalmol Vis Sci
Chronic wound state exacerbated by oxidative stress in Pax6+/- aniridia-related keratopathy
J Pathol
Cell surface glycoconjugate abnormalities and corneal epithelial wound healing in the Pax6+/- mouse model of aniridia-related keratopathy
Invest Ophthalmol Vis Sci
In vivo confocal microscopy of normal conjunctiva and conjunctivitis
Cornea
Laser scanning in vivo confocal microscopy of the normal human corneoscleral limbus
Invest Ophthalmol Vis Sci
Cited by (39)
Future directions in managing aniridia-associated keratopathy
2023, Survey of OphthalmologyRitanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model
2021, Biochemical and Biophysical Research CommunicationsAniridia and the ocular surface: medical and surgical problems and solutions
2021, Archivos de la Sociedad Espanola de OftalmologiaCongenital aniridia – A comprehensive review of clinical features and therapeutic approaches
2021, Survey of Ophthalmology
Manuscript no. 2011-1617.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
A European Union Marie Curie Fellowship (to N.L.). Funding support from Crown Princess Margareta's Foundation for the Visually Impaired, the Swedish Eye Fund, Carmen and Bertil Regnérs Foundation, and David and Beth Dahlins Foundation to UE. Support from King Gustav V and Queen Victoria's Freemasons Foundation, the County Council of Östergötland, and the Association of the Blind in Östergötland (to P.F.). The funding organizations had no role in the design or conduct of this research.